1	2		3.
13	M/s. Fulford (I) Ltd. (Gantamycin).	194.62	
14	M/s. Nicholas Labs. (Gentamycin)	53.03	
15	M/s. Burroughs Wellcome (Sulphamathoxazole).	441.27	
16	M/s. Lyka Labs. (Fluocinolone Acetonide)		678.73
17	M/s. Glaxo India Ltd. (Betainethasone & Salts)	7178.18	

Basis of drug prices equalisation account's claims

1622. SHRI H. HANUMANTHAPPA: CHOWDHARY RAM SEWAK:

Will the PRIME MINISTER be pleas ed to state: '..-.-

(a) whether it is a fact that M/s. Glaxo created a provision of Rs. 30.87 crores in their balance sheet for the year 1988-89 for DPEA claims based on the Judgement of High Court;

(b) whether it is also a fact that this money was used by the company without any interest and no income tax was paid; and

(c) what is the break, up of this amount yearwise?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) The information as supplied by the Company itself regarding provision made in its books for DPEA claims is given in the statement attached. The matter relating to recoveries from. M/s. Glaxo is the subject matter of a Writ Petition in the Delhi High Court and is, therefor sub-judice.

Statement

Yearwise Details of provisions in the Books for DPEA Claims Rs. in Lakhs

	Provision for the year	Cumulative
		485.77
1982-83	481.13	966.90
	526.76	1493.66
1984-85	612.33	2105.99
	680.64	2786.63
1985-87 (Net of writeback arising ou o f Order of 20-11-86)	770.57	2957.29
		3085.8 4
1938.89 (Writeback arising out of order of 2-1-89)	522.74	2563-10